Crohn Disease

Automatic Bibliography Maker

If you log out, you will be required to enter your username and password the next time you visit. In the United States, where food product labeling requires language approval by the FDA, probiotic manufacturers have received warning letters for making disease or treatment claims. Prentice Hall International, London. There was also a very likely negative effect of BOHB on glucose in both groups. Expected primary payers include: Low-dose CT examinations in Crohn's disease:

ISBN13: 978-1259087271

Environmental influences such as tobacco use seem to have an effect on Crohn disease. Smoking has been shown to double the risk of Crohn disease, whereas the risk of developing ulcerative colitis is lower in people who smoke than in those who have never smoked or in those who stopped smoking before their diagnosis. It has been suggested that a diet high in fatty foods may increase the risk of Crohn disease.

In , the prevalence of Crohn disease in the United States was estimated on the basis of data from Olmstead County, Minnesota, and was approximated at 8 cases per , population. Urban areas may have a higher prevalence of IBD than rural areas do. This difference in incidence correlates with the highest frequency of IBD in temperate climates and more industrialized parts of the world, such as Western Europe and North America.

The overall incidence of Crohn disease in Europe is about 5. Increases are reported from some high-incidence areas eg, Denmark and Sweden. Earlier studies from the s reported an incidence of 4. Incidence figures in Asia range from 0.

A systematic review revealed that the highest prevalence for Crohn disease in North America was per , persons, compared with per , persons in Europe. The age of onset of Crohn disease has a bimodal distribution. The first peak occurs between the ages of 15 and 30 years late adolescence and early adulthood , and the second occurs mainly in women between the ages of 60 and 70 years.

A greater proportion of colonic and distal Crohn disease has been diagnosed in older patients, whereas younger patients have predominantly ileal disease. In general, the frequency of IBD is similar in males and females, with some studies showing a very slight female predominance. The rate of Crohn disease is 1. In Japan, a male predominance exists. Crohn disease is reported to be more common in white patients than in black patients and rare in Asian and Hispanic children. Rates are higher in people of Jewish descent, particularly in Ashkenazi Jews and Jews of middle European origin as compared with Sephardic or eastern European Jews.

Crohn disease is a chronic inflammatory condition with an indolent course. Appropriate medical and surgical therapy helps patients to have a reasonable quality of life, with an overall good prognosis and an extremely low risk of a fatal outcome.

Several earlier studies estimated a slight decrease in life expectancy associated with certain prognostic indicators, such as female sex, long disease duration, and disease location. The increased mortality was related to pulmonary malignancies, genitourinary tract diseases, and GI, liver, and biliary diseases. In contrast, other studies have reported normal survival in patients with Crohn disease.

With the advent of new medical therapies, population-based studies have shown that overall survival for North American patients with IBD is similar to that expected in the US white population. Crohn disease is typically characterized by periods of remission and relapse.

Patients with proximal small bowel disease have a higher risk of mortality than those who have ileal or ileocecal disease. The excess mortality may be ascribed to complications of Crohn disease. Acute Crohn disease of the terminal ileum is often discovered during laparotomy for suspected appendicitis and has an excellent prognosis. The acute episode is usually treated conservatively, and as many as two thirds of patients may show no subsequent evidence of regional enteritis.

Discussion of the diagnosis, management, and surveillance of colorectal cancer in patients with IBD is beyond the scope of this article. Current data suggest that with the advent of improved therapies for patients with IBD, there is a trend toward decreasing risk of colorectal cancer. For more information, see the following 2 guidelines:. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.

Accessed September 11, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn disease or adenomas. Genetic studies are yielding evidence associating particular variants of the CARD15 gene with the prognosis of Crohn disease. Education of patients and their families is encouraged and is extremely important in the treatment process. Useful education materials can be obtained from the following organization:. Pathophysiology, Diagnosis, and Management.

WB Saunders Co; Current Medical Diagnosis and Treatment. McGraw-Hill Professional Publishing; Academic achievement, attendance, and school-related quality of life in pediatric inflammatory bowel disease. J Dev Behav Pediatr. Quality of life in children with Crohn's disease. J Pediatr Gastroenterol Nutr. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Practice parameters for the surgical management of Crohn's disease. Clinical patterns in Crohn's disease: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: Role of genetics in the diagnosis and prognosis of Crohn's disease.

Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: Surg Clin North Am. Evidence-based clinical practice guidelines for inflammatory bowel disease. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility.

Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p Wellcome Trust Case Control Consortium. Genome-wide association study of 14, cases of seven common diseases and 3, shared controls. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: Endoscopic surveillance in Crohn's disease and ulcerative colitis: Adalimumab for maintenance treatment of Crohn's disease: Smoking in Crohn's disease: Dietary patterns and risk for Crohn's disease in children.

Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: Arch Pediatr Adolesc Med. Appendectomy is more frequent but not a risk factor in Crohn's disease while being protective in ulcerative colitis: Crohn's disease in Olmsted County, Minnesota, The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

Incidence of inflammatory bowel disease across Europe: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Trends in incidence rates of ulcerative colitis and Crohn's disease.

Update on the genetics of inflammatory bowel disease. Survival and cause specific mortality in patients with inflammatory bowel disease: Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from to Intestinal cancer risk and mortality in patients with Crohn's disease.

Friedman S, Blumberg RS. Harrison's Principles of Internal Medicine. Diagnosis and management of Crohn's disease. Extraintestinal manifestations in inflammatory bowel disease.

Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from to The prevalence of extraintestinal diseases in inflammatory bowel disease: How prevalent are extraintestinal manifestations at the initial diagnosis of IBD?.

Inflammatory bowel disease in Iran: A simple classification of Crohn's disease: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Short pediatric Crohn's disease activity index for quality improvement and observational research.

World Gastroenterology Organisation global guidelines inflammatory bowel disease: World Gastroenterology Organisation global guideline: World Gastroenterology Organisation; New IBD guidelines aim to simplify care. February 20, ; Accessed: Risk stratification of emergency department patients with Crohn's disease could reduce computed tomography use by nearly half.

Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: Low-dose CT examinations in Crohn's disease: Impact on image quality, diagnostic performance, and radiation dose. Diagnostic accuracy of computed tomography using lower doses of radiation for patients with Crohn's disease. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.

Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis.

New diagnostic imaging tools for inflammatory bowel disease. Imaging of the small bowel in Crohn's disease: Modern imaging using computer tomography and magnetic resonance imaging for inflammatory bowel disease IBD AU1. Imaging recommendations for patients with newly suspected Crohn's disease, and in patients with known Crohn's disease and acute exacerbation or suspected complications.

American College of Radiology. American College of Radiology; Magnetic resonance imaging in Crohn's disease. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Magnetic resonance imaging for evaluation of Crohn's disease: Crohn disease of the small bowel: J Magn Reson Imaging. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease.

Diagnostic and therapeutic impact of MR enterography in Crohn's disease. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas.

The evaluation and treatment of Crohn perianal fistulae: Gastroenterol Clin North Am. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. Optimizing therapy for inflammatory bowel disease. Stem cell transplantation halts Crohn's disease. May 22, ; Accessed: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med.

Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. Glucocorticosteroid therapy in inflammatory bowel disease: Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Efficacy of biological therapies in inflammatory bowel disease: US Food and Drug Administration. Posted September 7, Meta-analysis comparing the efficacy and adverse events of biologics and thiopurines for Crohn's Disease after surgery for ulcerative colitis.

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Infliximab for the treatment of fistulas in patients with Crohn's disease. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.

Crohn's Disease cA2 Study Group. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: Human anti-tumor necrosis factor monoclonal antibody adalimumab in Crohn's disease: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: Anti-interleukin antibody for active Crohn's disease.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults. Certolizumab pegol for the treatment of Crohn's disease. Maintenance therapy with certolizumab pegol for Crohn's disease. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. New risk factor for progressive multifocal leukoencephalopathy PML associated with Tysabri natalizumab [safety announcement].

Natalizumab induction and maintenance therapy for Crohn's disease. Natalizumab for the treatment of active Crohn's disease: Vedolizumab as induction and maintenance therapy for Crohn's disease. FDA clears ustekinumab Stelara for Crohn's disease. September 26, ; Accessed: A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn's disease patients: Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: Metabolic bone disease in inflammatory bowel disease.

Enteral nutrition in Crohn disease: Razack R, Seidner DL. Nutrition in inflammatory bowel disease. International survey of enteral nutrition protocols used in children with Crohn's disease.

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: Alos R, Hinojosa J. Timing of surgery in Crohn's disease: A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease.

Managing medical complications and recurrence after surgery for Crohn's disease. Atlas of General Surgical Techniques. Safety and efficacy of strictureplasty for Crohn's disease: Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: Abscesses in Crohn's disease: Acute surgical emergencies in inflammatory bowel disease.

The role of primary surgical procedure in maintaining intestinal continuity for patients with Crohn's colitis. Perianal fistulizing Crohn's disease: Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Laparoscopic surgery for inflammatory bowel disease. Laparoscopy for inflammatory bowel disease: Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung's disease: Is there any difference in recurrence rates in laparoscopic ileocolic resection for Crohn's disease compared with conventional surgery?

A long-term, follow-up study. Laparoscopic colectomy compares favorably with colectomy by laparotomy for reduction of postoperative ileus. Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: Antibiotic therapy in inflammatory bowel disease: Induction therapy for ulcerative colitis: Livedo vasculitis with protein C system deficiency.

Livedo vasculopathy vs small vessel cutaneous vasculitis: Cytokine and platelet P-selectin studies. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs — A prospective study.

J Eur Acad Dermatol Venereol ; Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant.

High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa. A clinicopathological study of 27 patients. Changgeng Yi Xue Za Zhi ; The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. Livedoid vasculopathy associated with sickle cell trait: Significant improvement on aspirin treatment. Int Wound J ;9: Pentoxifylline Trental therapy for the vasculitis of atrophie blanche.

Ely H, Bard JW. Therapy of livedo vasculitis with pentoxifylline. Antiplatelet therapy in atrophie blanche and livedo vasculitis. J Am Acad Dermatol ;7: Response to t-PA therapy. Acta Derm Venereol ; Minidose heparin therapy for vasculitis of atrophie blanche. J Am Acad Dermatol ;8: Low-molecular-weight heparin in leg ulcers due to microangiopathy Results with curative doses in nineteen patients.

Semaine Des Hopitaux ; Treatment of livedoid vasculopathy with low-molecular-weight heparin: Report of 2 cases. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia.

Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: J Am Acad Dermatol ; Francès C, Barete S. Difficult management of livedoid vasculopathy. Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. J Thromb Thrombolysis ; Fibrinolysis induced by danazol. Danazol therapy in hypoplasminogenemia.

Response to low-dose danazol. Low-dose danazol in the treatment of livedoid vasculitis. Livedoid vasculitis with anticardiolipin antibodies: Livedoid thrombotic vasculopathy responding to doxycycline therapy. J Clin Aesthet Dermatol ;1: A ten-year retrospective study on livedo vasculopathy in Asian patients. Ann Acad Med Singapore ; Nifedipine treatment of idiopathic atrophie blanche. J Am Acad Dermatol ;14 5 Pt 1: Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methylenetetrahydrofolate reductase CT genotype: Results from a crossover trial.

Mol Nutr Food Res ; Clinical profile and treatment outcome of livedoid vasculitis: Response of livedoid vasculitis to intravenous immunoglobulin. Normal human polyspecific immunoglobulin G intravenous immunoglobulin modulates endothelial cell function in vitro.

Nephrol Dial Transplant ; Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol ; Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: An open trial evaluating 9 consecutive patients. Acta Med Port ; Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen. Long-term follow-up results following hyperbaric oxygen therapy.

Livedo reticularis and livedoid vasculitis responding to PUVA therapy. Livedoid vasculitis responding to PUVA therapy. Int J Dermatol ; Refractory livedoid vasculitis responding to PUVA: A report of four cases.